Supernus Pharmaceuticals and Indivior entered an all-stock “merger of equals” agreement to form a larger CNS-focused company, combining a portfolio of neuroscience and addiction medicines. The combined firm will operate under the Supernus name and is expected to close in the fourth quarter of 2026, with shareholders receiving a fixed exchange ratio and Indivior’s deal terms including a special cash dividend. The combined portfolio is expected to include 11 commercial CNS-targeting medicines, with Indivior’s Sublocade positioned as a major revenue driver. The structure reflects continued strategy in CNS pharma: build scale in mid-sized franchises while preparing for pipeline and label expansion. A related item underscored the same merger rationale and timing, highlighting cost-savings expectations and the companies’ shared focus areas.